Health services are replete with innovations promising improvements in care and outcome. 1 Realizing these benefits requires parallel evolution of clinical decision making, supported by objective, validated evidence. Improvements in troponin test performance are one such innovation, with the potential to disposition of emergency department (ED) patients presenting with suspected acute coronary syndromes (ACS) by facilitating earlier recognition of non-ST-segment elevation myocardial infarction, thereby reducing treatment delay, and through ruling out ACS allowing for earlier discharge. Unfortunately, clinical evidence has not kept up with the rate of biochemical assay advancement. Most of high-sensitivity troponin testing data focus on test performance, rather than the prospective and randomized evaluation of its impact on clinical outcome. Furthermore, international data continue to suggest that widespread unguided implementation of high-sensitivity troponin testing in EDs is not cost-effective. 4, 5 Nevertheless, protocols using the change in troponin over 1 hour from hospital presentation using high-sensitivity troponin assays have been developed and are advocated in the European Society of Cardiology Guidelines for the management of non-ST-segment elevation ACS. 6, 7 These protocols suggest that up to 60% of patients may be safely discharged from the ED more rapidly than traditional care. To date, current large published studies using 1-hour protocols have been observational. 7, 8 These studies have not evaluated prospective patients clinically managed according to the troponin protocols and did not include a randomized control. To address this, we have designed and initiated a pragmatic randomized trial that will comprehensively evaluate the safety, clinical effectiveness, and resource implications of a 1-hour protocol using high-sensitivity troponin T (hs-TnT) in the care of patients with suspected ACS.
Methods

Primary objective and hypothesis
The primary aim of this study is to determine the relative effectiveness of a 0/1-hour hs-TnT protocol compared with current standard care for patients with suspected ACS within the ED in terms of 30-day all-cause mortality or new/ recurrent ACS admission. Secondary aims are to determine if patients with suspected ACS discharged from the ED in accordance with a 0/1-hour hs-TnT protocol have an acceptably low rate of death or new/recurrent ACS by 30 days, compared with the existing treatment, and to evaluate the health system cost-effectiveness of an hs-TnTbased strategy at 12 months.
The primary hypothesis is that in comparison to standard care using conventional TnT reporting, risk assessment and clinical care based on a 0-hour/1-hour hs-TnT protocol will provide noninferior clinical outcomes at 30 days, with less total cost at 12 months. The secondary hypothesis is that clinical management of patients with suspected ACS discharged from the ED under the 1-hour hs-TnT protocol is safe with a 30-day death or new/recurrent ACS of b1%.
Study design
This is a prospective randomized trial (n = 5,400, 5 hospitals) of the European Society of Cardiology (ESC) guideline-advocated TRAPID-AMI 1-hour hs-TnT protocol for undifferentiated chest pain 6, 7 ( Figure 1 ). To maintain the integrity of the testing protocols in each study arm, randomization to troponin reporting formats will occur before any troponin assays are undertaken. The primary composite end point is all-cause death or new/recurrent ACS by 30 days, and clinical events will also be determined within 12 months of follow-up. Participant eligibility is described in Table I . This study is registered with Australian and New Zealand Clinical Trial Registry (Reg. No. ACTRN12615001379505).
Intervention: clinical disposition and care determined by the hs-TnT result
For patients randomized to the 0/1-hour hs-TnT protocol, hs-TnT report results will determine the patients care pathway. Baseline and a 1-hour hs-TnT formatted sample will determine the patient's disposition based on the TRAPID-AMI protocol ( Figure 2 ): (a) rule-out, baseline troponin b5 or b12 ng/L and change in troponin over 1 hour of b3 ng/L: discharge to primary care with instructions regarding repeat episodes of chest pain and primary prevention advice; (b) rule-in, baseline troponin ≥52 ng/L or a change over 1 hour of ≥5 ng/L: admit to hospital for management of MI; (c) observe, baseline troponin between 13 and 51 ng/L and a change Study schematic with anticipated rates of admission and discharge of patients from the ED and populations of patients to be used to assess study aims.
over 1 hour of b5 ng/L, or baseline troponin of b12 ng/L and a change over 1 hour of 3-4 ng/L: admit to an inpatient unit.
7 Subsequent testing will be determined by treating clinicians, although application of the National Institute for Health and Care Excellence guidelines will be recommended. 9 These guidelines make recommendations regarding functional or invasive coronary testing based on characterization of chest pain and cardiovascular risk factors.
Control arm: current standard of care
Based on current and emerging guidelines, patients randomized to standard care will receive troponin testing at baseline, which will be repeated at 3 hours after presentation (with further testing at clinician discretion), with results reported according to the conventional lower reference limit (30 ng/L). 10 Patients randomized to the best current care will have their disposition determined by the treating ED clinician. The control arm report does not have sufficient troponin profile information to safely implement the 1-hour protocol, preventing contamination between randomized study arms.
Access to outpatient care will be as per local practice. Subsequent care will be physician-determined.
Controlling exposure of the hs-TnT reporting
Potential study participants will be identified by a senior ED clinician and trial eligibility will be assessed at the end of the initial medical assessment. The enrolling and/or treating physician will complete the EDACS risk scoring information.
11 Consenting patients will be randomly allocated to either the current conventional troponin T report and physician-directed care, or the 0-hour/1-hour hs-TnT determined management care pathway. Block randomization in blocks of 4 within hospital sites will be performed to ensure balance between study arms by location. The randomization schedule will be generated by an independent statistician and will be implemented by a sealed envelope process.
Pathology services for all South Australian public hospitals are provided by a centralized provider (SA Pathology), enabling uniformed management of the 2 troponin reporting formats. The Roche, Basel Switzerland Diagnostics (Cobas) Elecsys fifth-generation hs-TnT assay (detection limit: 3 ng/L, 99th percentile: 14 ng/L) has been in use since April 2010. However, SA Pathology currently reports troponin results to levels numerically aligned with the fourth-generation assay (ie, normal 30 ng/L, with levels b30 ng/L reported as "≤29 ng/L") rather than the absolute level. Although it is recognized that a level of 30 ng/L is comparable to~50 ng/L using the fourth-generation assay, clinical decision making based on this level is now established in practice. 12 Furthermore, although the clinical use of the more sensitive troponin level does potentially narrow the contrast between the study arms, the potential value of the Reported performance of rule-in/rule-out M protocol using 0-hour/1-hour hs-TnT testing.
7 Table II . Study outcomes definitions
Definitions
All-cause mortality Death form any cause CV mortality Death due to myocardial infarction, sudden cardiac death, heart failure or cardiogenic shock, stroke, and other causes including pulmonary embolism or aortic aneurysm rupture New/recurrent MI ⁎ New MI: a rise and/or fall of biomarkers with at least one value above the 99th percentile of the URL with at least one of the following • In participants without MI at admission, an MI after enrollment but before angiography will be diagnosed when any elevation of troponin or CK-MB N ULN occurs (or CK N ULN in the absence of MB determination).
• In participants with MI at presentation, in whom the elevated troponin or CK-MB (or CK) levels are documented to be falling or have returned to normal, diagnosis of a second MI requires: Unstable angina Chest pain/discomfort with an accelerated pattern or occurring at rest, associated with dynamic ECG changes consistent with ischemia; or functional testing consistent with ischemia; and/or demonstrated coronary stenosis N70% by visual estimation. Unplanned hospital admission Nonelective coronary revascularization; cerebrovascular accidents; atrial or ventricular arrhythmias; congestive cardiac failure without MI; as documented by a hospital discharge summary at 30 d and 12 mo Bleeding TIMI major/minor/minimal bleed:
• Major: overt clinical bleeding (or documented intracranial or retroperitoneal hemorrhage) associated with a drop in hemoglobin of N5 g/dL (50 g/L) or a hematocrit of N15% (absolute) • Minor: overt clinical bleeding associated with a fall in hemoglobin of 3 g/dL to 5 g/dL (50 g/L)
or a hematocrit of 9% to ≤15% (absolute) • Minimal: any clinically overt sign of hemorrhage (including imaging) that is associated with a b3-g/dL decrease in the hemoglobin concentration or b9% decrease in the hematocrit GUSTO bleeding classification • Severe or life-threatening: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention • Moderate: bleeding that requires blood transfusion but does not result in hemodynamic compromise • Mild: bleeding that does not meet criteria for either severe or moderate bleeding 0-hour/1-hour protocol under investigation, resides in its ability to leverage small changes in troponin at early time points to aide clinical decision making, and a characteristic that is not present in the control arm. The fifth-generation hs-TnT reporting format will only be reported for those patients randomized to the investigational management arm.
Data collection and outcome measures
All patients will be followed up to assess the frequency of diagnostic procedure(s)/service(s) at initial presentation and during follow-up (eg, stress testing, echocardiography, invasive investigation, and revascularization), ED length of stay (LOS), inpatient health care/total LOS, outpatient health care attendance(s) (ie, general practitioner and specialist attendances), readmission(s), and the use of guideline-recommended pharmacotherapies. Patients will be assessed for ED and total hospital LOS, readmission, and all aspects of resource utilization including ongoing imaging and pathology services. At 30 days, 6 months, and 12 months, patients will be contacted by telephone and assessed for vital status, rehospitalization and quality of life (EQ-5D). Evidence of South Australian readmissions will be sourced from centralized public and private South Australian hospital data.
The primary effectiveness measure will be the incidence of composite of all-cause mortality new/recurrent ACS (ie, readmission for MI or unstable angina) within 30 days of randomization. Key secondary end points will be the incidence of primary end point composite by 12 months, components of the primary end point by 30 days and 12 months, and cardiovascular rehospitalization, bleeding events, and resource utilization for health economic evaluation. The definition of outcome measures is described in Table II . Enrollment commenced in December 2015 and there are currently 796 randomized within the study from 2 centers. The anticipated "last patient-in" is December 2018, with "last patient-out" of 30-day follow-up in January 2019, and last patient-out of 12-month follow-up in January 2020. Baseline clinical characteristics and measures of protocol adherence are presented in Table III .
Ethical considerations and study governance
Ethics approval has been received from the Southern Adelaide Clinical Human Research Ethics Committee, with mutual acceptance covering all other sites involved. All patients will be asked to provide informed consent. The steering committee of emergency physicians, emergency and cardiology nurses, cardiologists, implementation experts, and clinical pathologists with representation from each of the participating hospitals is providing oversight to the study. Data management is centralized at Health Systems Research group of Flinders University. An independent Data and Safety Monitoring Board is reviewing all in-hospital and postdischarge (≤7 days) clinical events including representations to hospital. A Clinical Event Adjudication Committee, independent of the study management team, is providing blinded evaluation (events deidentified for treatment arm, hospital, and patient details) of all components of the primary end point including index (within 24 hours of initial presentation) and subsequent MI. The study will frequent Data and Safety Monitoring Board review of events rates to ensure patient safety, leveraging the existing administrative data infrastructure to facilitate event adjudication.
Study funding
This is an investigator-initiated study funded by the National Health and Medical Research Council of Australia (APP1124471) with additional funding through an unrestricted grant from Roche Diagnostics (Basel Switzerland). Roche Diagnostics were approached after the study was designed, ethical approval gained, and • Intracranial or intraocular • Reduction in hemoglobin of ≥4.0 g/dL without an overt source of bleeding, or of ≥3.0 g/dL with an overt source of bleeding • Use of any blood product transfusion • Hematoma ≥5 cm in diameter, reoperation for bleeding, access site hemorrhage requiring intervention Bleeding events will also be classified using the BARC bleeding classification. 30 Health economic evaluation o Measures of in-hospital care: stress testing, echocardiography, coronary angiography, cardiac medications at discharge consistent with guidelines o Health-related quality of life (EQ-5D-5L) at 30 d, 6 mo, and 12 mo
Resource utilization over 12 mo: Medicare data among consenting patients using MBS, medication use from PBS and inpatient admissions from the AN-DRG version 6.0.
Abbreviations: CV, cardiovascular; URL, Upper reference limit; LBBB, left bundle branch block; CK-MB, creatine kinase-myocardial band; ULN, upper limit of normal; PCI, percutaneous coronary intervention; cTn, cardiac troponin; CABG, coronary artery bypass grafting; TIMI, Thrombolysis in Myocardial Infarction; GUSTO, Global utilization of streptokinase and TPA for occluded coronary arteries; ACUITY, Acute catheterization and urgent intervention triage strategy; BARC, Bleeding academic research consortium. ⁎ NB: hs-TnT elevations will undergo blinded adjudication for MI to confirm event time. All in-hospital MIs occurring during the index presentation will be excluded from the primary outcome. Adjudicated MIs will be subclassified using the Third Universal definition of MI criteria. 29 enrollment commenced, and their contribution was not dependent on any protocol modification or direct access to the study data.
Sample size determination
An earlier study published by in this population observed primary end point 30-day rate of 2.1% (20/945) for all patients and 1.5% (12/811) among those with an initial troponin b30 ng/L under the standard arm. 13 Approximately 40% of patients were discharged directly from the ED. The event rate among those discharged directly from ED within the hs-TnT arm of this study was 0.3% (1/368), while in TRAPID-AMI, it was 0.1%. 7 In the TRAPID-AMI study, direct discharge from the ED was reported in~60% of patients. In addition, ED physicians report an "acceptable" 30-day missed death or MI rate of less than 1%. 14 Consequently, assuming a primary end point in the active arm of 0.3% and a 60%/40% ED discharge ratio, a sample size of 1,212 ED discharged patients in the active arm and 808 ED discharged patients in the control arm (total n = 2,020) provides 80% power to demonstrate the noninferiority of hs-TnT to standard TnT, assuming a "clinically acceptable 1% absolute rate" (ie, noninferiority margin of 0.7%).
However, several other factors required further consideration in the sample size estimation. First, a further 2,020 patients not discharged from the ED (ie, those 40% and 60% of patients admitted, died, and transferred) contribute to the primary analysis (total n = 4,040). Second, our previous experience has shown that 22% of patients present with a troponin ≥30 ng/L, and because these patients receive little difference in reporting protocols and care between study arms, this dilutes study power. Accounting for these patients and a 3% attrition rate by 12 months as previously seen, a sample size of 5,400 is planned. Third, with very low event rates, relative effect sizes have limited clinical relevance. Hence, an absolute effect size based on a "number needed to treat" under the new protocol of 100 (ie, 1% absolute reduction) has been chosen as an addition design goal. If the control arm event rate is as low as 1.5% among patients with troponin b30 ng/ L, this sample size (n = 5,400) has 80% power to detect a 1% absolute reduction (ie, 27 fewer events) in the 30-day primary end point and 86% power to detect this same absolute reduction (ie, 21 fewer events) among patients with an initial troponin b30 ng/L (n = 4,040). The study has N80% power to demonstrate that for 12-month follow-up, the hazard ratio for time to the primary end point between the 2 groups is no worse than 2. An interim analysis to assess the overall primary end point event rate among patients discharged from the ED in the active arm will be conducted at 2,000 patients (ie, estimated 750 patients discharged from the ED under the active arm) to assess safety of discharge under the 0-hour/1-hour protocol and overall events rates.
Assuming no difference in quality of life and an SD in costs of $3,000, the health economic analysis has N90% power to detect a difference of $650 dollars per patient assessed. All sample size calculations assume a type I error rate of 5%.
Methods of statistical analyses
The primary analysis will use the intention-to-treat population including all randomized patients. Given the noninferiority design of secondary safety question, this analysis will use the per-protocol population defined as protocol compliant and discharged from ED, with a sensitivity analysis undertaken using the intention-to-treat population. The study will be reported according to CONSORT guidelines. Overall effectiveness of care under the 0/1-hour hs-TnT protocol compared with standard care will be assessed using negative binomial regression with robust standard errors. Twelve-month freedom from mortality, recurrent ACS will be assessed by Cox regression survival analysis using shared frailty models to account for correlated results within hospitals. Comparisons of the proportions of patients receiving various investigations and revascularization will be compared using univariate and multivariate random-effects logistic regression, again clustering over hospitals. Furthermore, subanalysis will be confined to patients with an initial troponin b30 ng/L, that is, in the range where troponin reporting format (eg, actual level 5-29 ng/L vs ≤29 ng/L) differs between the 2 study arms. The key secondary noninferiority analysis will determine if the incidence rate among the patients discharged under the 0/1 hour hs-TnT protocol is not inferior to the accepted ED standard of 1.0% by examining whether upper confidence bound of the incidence rate difference crosses 0.7%. Economic Analysis: Analysis will be undertaken from the viewpoint of the health funders (ie, State Health Departments [Diagnosis-Related Groups, or DRGs], Medicare Benefits Scheme [MBS] , and Pharmaceutical Benefit Scheme [PBS]). Within-trial incremental costs associated with hs-TnT reporting compared with the conventional TnT report will be estimated using federal reimbursements for primary care (MBS), pharmaceutical (PBS), and private hospital costs (DRG), and centralized costing data for inpatient and outpatient episodes at public hospitals (DRG). Within-trial cost-effectiveness with respect to the primary clinical outcome and quality-adjusted life years (QALYs) will be analyzed with primary outcome being incremental cost per primary clinical outcome avoided and secondary outcome being incremental cost per QALY gained. Utility will be assessed using EuroQol-5 Dimension-5 Level (EQ-5D-5L) with UK valuation measured at baseline, 3 months, 6 months, and 12 months. 15 Patient-level measures of utility derived from the EQ-5D instrument will be integrated with survival curves using the quality-adjusted survival analysis method over the 12-month period. 16 Nonparametric bootstrapping estimates of mean difference in cost and effects (events avoided and QALY gained) from patient-level data will be performed to account for uncertainty due to sampling variation in cost-effectiveness. "It is recognized that demonstrating a significant reduction in QALYs over the 12-month period is not anticipated, but the hypothesized impact on avoided MIs suggests that important differences in costs and QALYs will not be captured over the trial time horizon. Relevant data sources and literature will be sought to extrapolate the longer-term costs and benefits derived from observed differences in cardiovascular events to generate full estimates of the cost-effectiveness of the 1hr hs-TnT protocol compared to the standard 6 hr protocol."
The authors are solely responsible for the design and conduct of this study including study analyses, the drafting and editing of the manuscript, and its final contents. Each author has been directly contributed to the design and conduct of the study and has approved the manuscript.
Discussion
Within Australia, chest pain and suspected ACS represent 10% of the nearly 8 million ED presentations every year; yet up to 85% of these patients do not have ACS. 17 Importantly, time-consuming assessment may contribute to ED overcrowding, drawing clinical resources away from patients with more critical clinical conditions, resulting in increased morbidity and mortality. The challenge faced by ED staff focuses on rapid risk assessment to determine patient disposition. Without objective evidence of ischemia, this decision is often difficult. It is well understood that evolving ACS cannot be excluded on clinical grounds alone, and electrocardiogram (ECG) changes are frequently misinterpreted, with nearly half of the patients with MI presenting with normal or nonspecific ECG changes. 18, 19 Decisions to admit patients without objective coronary ischemia for further testing (most patients) are hampered by limited hospital beds and finite testing resources. Of note, the potential for unnecessary procedures and iatrogenic harm from the investigation of patients with low-risk chest pain is a significant concern. A US study of 421,774 ED presentations demonstrated an increase in MI and revascularization associated with several testing strategies when compared with no investigations. 20 Conversely, the decision to discharge patients early is fraught with the risk of missed MI and its attendant consequences. 21 Unsurprisingly, the resources expended to prevent missed MI are substantial. 17 Merely reporting troponin results to levels achievable with an hs-TnT assay did not translate to more effective decision making and improved 30-day clinical outcomes, although an unexplained modest reduction in 12-month mortality may be evident. 13 Consequently, routine hs-TnT reporting was not cost-effective (ICER: $193,135/QALY gained). Translating these innovations effectively into routine practice is undeniably complex. Therefore, it is not surprising that hs-TnT approval in the United States has only recently occurred, whereas local (Australian Health Technology Assessment Agency) and international bodies (ie, Canada Agency for Drug and Technologies in Heath, and National Institute for Health and Care Excellence in the United Kingdom) continue to call for more randomized evaluations of the true impacts of decision-making protocols integrating high-sensitivity troponin assays. 4, 5 Several decision rules and risk-scoring algorithms have previously been developed to facilitate early discharge for patients with suspected ACS. 22, 23 These protocols have performed well in single-arm, uncontrolled studies, but interpreting the effectiveness and cost-effectiveness has been hampered by the lack of randomized trials. [23] [24] [25] Zero-hour/1-hour protocols based on troponin T and I have received particular international attention due to their ability to potentially identify up to 60% of patients suitable for early discharge at 1 hour. 7, 26 Despite continued debate, these protocols have been adopted into the ESC non-ST-segment elevation ACS guideline. 6 Although promising, their uncontrolled single-arm design leaves several issues that limit confidence in their implementation. First, these studies have needed to be selective in their patient recruitment, resulting in an underrepresentation of more complex patients. Second, the patients were not managed in accordance with the results, relying on post hoc analysis of bio-banks. Third, the utility of the protocol remains uncertain across the full range of "pretest probability" for ACS observed in clinical practice. This latter point is of particular relevance when making patient-specific recommendations based on well-established clinical criteria. 19 Fourth, very few patients with MI presented early (within 2 hours of onset) and the utility of the rule-out recommendations at this early timepoint remain uncertain. Fifth, the "rule-in" MI aspects of this protocol may be overinclusive and may lead to low-value investigation of patients with nonspecific myocardial injury rather than true type 1 MI. Although a small randomized study of a 0-hour/1-hour (n = 542) has demonstrated feasibility of early discharge, this study had insufficient power to address clinical events. 27 Furthermore, retrospectively applying the current ESC guideline-advocated hs-TnT "rule-in/rule-out" criteria to chest pain cohort collected across several centers highlights a suboptimal rule-out performance of an hs-TnT protocol with a negative predictive value of 97.1% (94.0%-98.0)%, suggesting that up to 3% of MIs may be missed MI.
The study has been designed to specifically address the equipoise of key decision makers where evidence is required to support implementation. Specifically, clinicians require evidence that subsequent investigation and management under such a decision rule improves overall outcomes in all patients with suspected ACS. Similarly, emergency physicians require robust evidence of the safety of the 0-hour/1-hour protocol in identifying patients for discharge, whereas health service providers require evidence that implementing a rapid troponin protocol leads to efficient care. Assay level, but not practice-level comparisons of 0-hour/1-hour protocols continue to show improved diagnostic performance. 7, 26, 28 Although a cluster-randomized trial assessing the impact of a high-sensitivity troponin I assay has been initiated, this hospital-level randomization may be less efficient for interpreting the interaction between the investigational protocol and patient risk. Hence, this patient-level randomized controlled design, uniquely controlling the reporting of hs-TnT results and blinded-end point adjudication is essential to interpret impacts on clinical practice, interactions with patient risk; evaluate overall effectiveness (and potential iatrogenic events); and robustly evaluate efficiency. Prospective and randomized comparison of these protocols is warranted before widespread implementation can be broadly advocated.
Conclusion
Challenges in risk-stratifying emergency patients with symptoms of suspected ACS may lead to inappropriate discharge and missed MI, whereas unnecessary admission can result in overinvestigation and iatrogenic harm. Demonstrating that a rapid hs-TnT protocol improves the appropriateness, effectiveness, and efficiency of care within a robust comparative study will fill a challenging evidence gap that currently limits the translation of more precise hs-TnT testing into better patient and health service outcomes.
